Showing results (221-230 of 442) with videos related to
Sort By:
Pageof 45
Inflammatory Bowel Diseases|August 21, 2023
The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative ColitisSimon Travis, Alison Potts Bleakman, Marla C Dubinsky, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 28, 2017
Asthma Is Associated With Subsequent Development of Inflammatory Bowel Disease: A Population-based Case-Control StudyM Ellen Kuenzig, Cheryl Barnabe, Cynthia H Seow, et al.Alimentary Pharmacology & Therapeutics|February 24, 2023
Meta-analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control armPatrick Hamilton, Katherine Buhler, John K MacDonald, et al.Journal of Crohn'S & Colitis|April 29, 2020
A Diversified Dietary Pattern Is Associated With a Balanced Gut Microbial Composition of Faecalibacterium and Escherichia/Shigella in Patients With Crohn's Disease in RemissionZhengxiao Zhang, Lorian Taylor, Nusrat Shommu, et al.Gastroenterology|October 18, 2011
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic reviewNatalie A Molodecky, Ing Shian Soon, Doreen M Rabi, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 29, 2020
Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016)Christopher Ma, Matthew K Smith, Leonardo Guizzetti, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2019
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug DevelopmentWalter Reinisch, Klaus Gottlieb, Jean-Frederic Colombel, et al.Gastro Hep Advances|August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 StudiesLaurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.Gut|January 7, 2011
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialWalter Reinisch, William J Sandborn, Daniel W Hommes, et al.Med (New York, N.Y.)|October 5, 2024
Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitisVirginia Solitano, Remo Panaccione, Bruce E Sands, et al.Pageof 45